Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Jupiter Neurosciences, Inc. (JUNS) had Consolidated Net Income/Loss of $-2.25M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-2.25M |
|
-- |
|
-- |
|
$2.26M |
|
$-2.26M |
|
$0.01M |
|
$-2.25M |
|
$-2.25M |
|
$-2.25M |
|
$-2.25M |
|
|
Consolidated Net Income/Loss |
$-2.25M |
$-2.25M |
|
$-2.26M |
|
$-2.26M |
|
33.18M |
|
33.18M |
|
$-0.07 |
|
$-0.07 |
|
| Balance Sheet Financials | |
$2.82M |
|
-- |
|
$1.15M |
|
$3.97M |
|
$2.63M |
|
-- |
|
-- |
|
$2.63M |
|
$1.34M |
|
$1.34M |
|
$1.34M |
|
34.83M |
|
| Cash Flow Statement Financials | |
$-1.89M |
|
-- |
|
-- |
|
$3.77M |
|
$1.88M |
|
$-1.89M |
|
$0.95M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.07 |
|
-- |
|
-- |
|
-- |
|
0.11 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.89M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-168.12% |
|
-168.12% |
|
-56.78% |
|
-168.12% |
|
$0.04 |
|
$-0.06 |
|
$-0.06 |
|